Noerr advises M.M.Warburg on rights offering by Epigenomics AG

12.11.2019

Noerr has advised M.M.Warburg & CO (AG & Co.) KGaA with respect to the bank’s role as the sole underwriter for a rights issue by Epigenomics AG, the Berlin-based molecular diagnostics company.

Based on a securities prospectus, 7,506,152 new Epigenomics shares were issued against cash contributions. The company will receive gross proceeds of EUR 8.3 million from the issue.

Noerr partner Stephan Schulz (Hamburg) coordinated the transaction. Noerr’s Capital Markets team has repeatedly advised M.M.Warburg on capital market transactions.

Advisors to M.M.Warburg: Noerr LLP

Dr Stephan Schulz (Hamburg, team lead), Dr Dominik Kloka (Capital Markets, Frankfurt), Dr Matthias Geurts (Tax, Frankfurt), Evelyn Schulz (Pharmaceutical, Dresden).

Associates: Dr Anca David, Dr Ramon Sieven, Juri Stremel (all Capital Markets, all Hamburg), Dr Armin Kühne (Patent Law, Munich), Susann Jahn (Pharmaceutical, Dresden)

PR team


Capital Markets

Share